IL6R and coronary artery disorder: This included positive control proteins targeted by drugs indicated for CHD, such IL6R (targeted by tocilizumab) and AT1B2 (targeted by digoxin), as well as a potential repurposing opportunity C1S (targeted by sutimlimab).<h4>Interpretation</h4>We have identified amino acid metabolism as an important contributing pathway to CHD risk.